Pfizer’s High Dividend Is Undervalued by the Market, and Investors May Be Facing a Good Opportunity to Position Themselves Oct 6, 2026 Life Science
Down 70%, Novo Nordisk Bets $3.9 Billion to Outrun Eli Lilly in the Weight-Loss Race Oct 2, 2026 Life Science
Johnson & Johnson Maintains Steady Dividends While Eli Lilly Bets on the Weight-Loss Drug Track Oct 2, 2026 Life Science
AbbVie vs. Bristol Myers Squibb: A Clash Between Growth Premium and Value Trap Oct 1, 2026 Life Science
Lilly and Viking Just Showed the Obesity Market’s Next Phase — and It’s Not About Pounds Sep 30, 2026 Life Science
Competition Fears Are Overblown, and Eli Lilly’s Growth Engine Remains Strong Sep 30, 2026 Life Science
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Backing China-Licensed Cancer Drug Sep 29, 2026 Life Science
Summit Secures $2 Billion Investment From AstraZeneca, and the Two Parties Will Jointly Develop Anti-Cancer Drugs Sep 28, 2026 Life Science
STAAR Surgical Announces $50 Million Buyback Plan, Stock Soars More Than 7% on Friday Sep 26, 2026 Life Science
ByteDance’s Anew Labs Emerges With $1.5B Valuation, Stirring New Questions Over AI Drug Discovery Sep 25, 2026 Life Science
Revolution Medicines Receives FDA Breakthrough Designation, Royalty Pharma Offers a Diversified Investment Path Sep 25, 2026 Life Science
BMY vs. JNJ: Low Valuation and High Yield or High Profit and Steady Growth? Sep 24, 2026 Life Science
AI Finds New Clues for Gene Editing, but It Is Still Far from a “New CRISPR” Sep 23, 2026 Life Science
